<!doctype html><html lang=en dir=auto><head><meta charset=utf-8><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1,shrink-to-fit=no"><meta name=robots content="index, follow"><title>OrgSyn011 | OrgSyn</title>
<meta name=keywords content><meta name=description content="本篇策略为卤代烯烃的硼氢化加成反应。原文：Org. Synth.  2023 ,  100 , 218-233."><meta name=author content="Argon"><link rel=canonical href=orgsyn-argon-gas.top/posts/orgsyn011/><link crossorigin=anonymous href=orgsyn-argon-gas.top/assets/css/stylesheet.9de45e225101e4f99701d2b68fc6b8a1ef6027928be6391fa15bf7f56326c909.css integrity rel="preload stylesheet" as=style><link rel=icon href=orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E><link rel=icon type=image/png sizes=16x16 href=orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E><link rel=icon type=image/png sizes=32x32 href=orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E><link rel=apple-touch-icon href=orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E><link rel=mask-icon href=orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E><meta name=theme-color content="#2e2e33"><meta name=msapplication-TileColor content="#2e2e33"><link rel=alternate hreflang=en href=orgsyn-argon-gas.top/posts/orgsyn011/><noscript><style>#theme-toggle,.top-link{display:none}</style><style>@media(prefers-color-scheme:dark){:root{--theme:rgb(29, 30, 32);--entry:rgb(46, 46, 51);--primary:rgb(218, 218, 219);--secondary:rgb(155, 156, 157);--tertiary:rgb(65, 66, 68);--content:rgb(196, 196, 197);--code-block-bg:rgb(46, 46, 51);--code-bg:rgb(55, 56, 62);--border:rgb(51, 51, 51)}.list{background:var(--theme)}.list:not(.dark)::-webkit-scrollbar-track{background:0 0}.list:not(.dark)::-webkit-scrollbar-thumb{border-color:var(--theme)}}</style></noscript><meta property="og:url" content="orgsyn-argon-gas.top/posts/orgsyn011/"><meta property="og:site_name" content="OrgSyn"><meta property="og:title" content="OrgSyn011"><meta property="og:description" content="本篇策略为卤代烯烃的硼氢化加成反应。原文：Org. Synth. 2023 , 100 , 218-233."><meta property="og:locale" content="en"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-02-15T17:11:29+08:00"><meta property="article:modified_time" content="2025-02-15T17:11:29+08:00"><meta property="og:image" content="orgsyn-argon-gas.top/%3Clink%20or%20path%20of%20image%20for%20opengraph,%20twitter-cards%3E"><meta name=twitter:card content="summary_large_image"><meta name=twitter:image content="orgsyn-argon-gas.top/%3Clink%20or%20path%20of%20image%20for%20opengraph,%20twitter-cards%3E"><meta name=twitter:title content="OrgSyn011"><meta name=twitter:description content="本篇策略为卤代烯烃的硼氢化加成反应。原文：Org. Synth.  2023 ,  100 , 218-233."><script type=application/ld+json>{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Posts","item":"orgsyn-argon-gas.top/posts/"},{"@type":"ListItem","position":2,"name":"OrgSyn011","item":"orgsyn-argon-gas.top/posts/orgsyn011/"}]}</script><script type=application/ld+json>{"@context":"https://schema.org","@type":"BlogPosting","headline":"OrgSyn011","name":"OrgSyn011","description":"本篇策略为卤代烯烃的硼氢化加成反应。原文：Org. Synth. 2023 , 100 , 218-233.\n","keywords":[],"articleBody":"本篇策略为卤代烯烃的硼氢化加成反应。原文：Org. Synth. 2023 , 100 , 218-233.\n简述 该反应表观上为烯烃的硼氢化过程。\n反应首先在低温下加入 BCl3 和 Et3SiH 实现硼氢化加成，然后冰浴条件下加水将硼烷水解，最后再用 KHF2 作为氟代试剂生成氟硼酸钾盐产物3。\n讨论 硼酸及衍生物在生物药物中常有出现，截至2023年底，美国食品药物管理局（FDA）已经批准了五个含硼的药物，分别是：Velcade®1; Kerydin2; Ninlaro®3; Eucrisa4; Vabomere5。\n硼在药物中应用的潜力来自于它的 Lewis 酸性，由于硼原子有一个空的 p 轨道，因此可以和 Lewis 碱相互作用，为其与酶的活性位点的氨基酸结合形成复合物提供了可能6。\n不过，硼的空轨道有时也会对合成造成影响，亲核试剂可能会被硼错误地捕获，无法起到原本的作用，因此人们逐渐探索出使用三氟硼酸盐来掩蔽硼的 Lewis 酸性的方法。\n卤代烷烃的硼氢化反应已有大量报导，但是现有的反应仍然存在许多不足之处，如原子经济性低、产率低、试剂昂贵或所得产物不纯等等7，因此仍需探索新的方案。\nBrown 等人发现二氯硼烷+二氧六环，以及二溴硼烷+二甲硫醚的组合在反应成本上有很大优势，但是由于二卤代硼烷的歧化，反应副产物很多，产率较低8。\n作者团队基于此方案继续优化，为避免歧化反应，他们使用三氯化硼+三乙基硅烷原位制备二卤代硼烷。但是后处理，纯化后得到的产物产率仍然不理想，这一点与底物碳链长度和溶解度有关系，长链化合物（如下图化合物2）因为在水中溶解度低因此容易结晶析出，产率较好（79%）；短链化合物产率不佳（化合物2b， 27%；化合物2c，22% ）。\n产物2再用氟氢化钾处理得氟硼酸钾盐产物3，Vedejs9 和 Molander10 等人的研究表明这一反应易于得到较好的产率（62-90%）。\n尽管得到了目标产物，但是两步反应的总产率并不高（14-71%），为提高反应的产率，作者团队再次进行了优化。最终，作者探索出了制备卤代烷烃氟硼酸钾盐的通用制备策略11（上图中上侧的一步反应），将原本的两步反应简化为一锅法实现，并对各类底物都表现出良好的适用性，副产物少，原子经济性高，价格低廉，有很大的应用潜力。\n参考 Baker, S. J.; Ding, C. Z.; Akama, T.; Zhang, Y. K.; Hernandez, V.; Xia, Y. Therapeutic potential of boron-containing compounds. Future Med. Chem. 2009, 1275-1288. ↩︎\n(a) Elewski, B. E.; Tosti, A. Tavaborole for the treatment of onychomycosis. Expert Opin. Pharmacother. 2014, 15, 1439-1448; (b) Hui, X.; Baker, S. J.; Wester, R. C.; Barbadillo, S.; Cashmore, A. K.; Sanders, V.; Hold, K. M.; Akama, T.; Zhang, Y. K.; Plattner, J. J.; Maibach, H. I. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J. Pharmaceut. Sci. 2007, 96, 2622-2631. ↩︎\nHu, Q.; Liu, R.; Fang, Z.; Zhang, J.; Ding, Y.; Tan, M.; Wang, M.; Pan, W.; Zhou, H.; Wang, E. Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci. Rep. 2013, 3, 2475. ↩︎\nHernandez, V.; Crépin, T.; Palencia, A.; Cusack, S.; Akama, T.; Baker, S. J.; Bu, W.; Feng, L.; Freund, Y. R.; Liu, L.; Meewan, M.; Mohan, M.; Mao, W.; Rock, F. L.; Sexton, H.; Sheoran, A.; Zhang, Y.; Zhang, Y.-K.; Zhou, Y.; Nieman, J. A.; Anugula, M. R.; Keramane, E. M.; Savariraj, K.; Reddy, D. S.; Sharma, R.; Subedi, R.; Singh, R.; O’Leary, A.; Simon, N. L.; De Marsh, P. L.; Mushtaq, S.; Warner, M.; Livermore, D. M.; Alley, M. R. K.; Plattner, J. J. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob. Agents Chemother. 2013, 57 (3), 1394-1403. ↩︎\nMessner, K.; Vuong, B.; Tranmer, G.K. The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry. Pharmaceuticals 2022, 15, 264. ↩︎\n(a) Baker, S. J.; Tomsho, J. W.; Benkovic, S. J. Boron-containing inhibitors of synthetases. Chem. Soc. Rev. 2011, 40, 4279-4285; (b) Das, B. C.; Thapa, P.; Karki, R.; Schinke, C.; Das, S.; Kambhampati, S.; Banerjee, S. K.; Vam Veldhuizen, P.; Verma, A.; Weiss, L. M.; Evans, T. Boron chemicals in diagnosis and therapeutics. Future Med. Chem. 2013, 5, 653-676. ↩︎\n(a) Soundararajan, R.; Matteson, D. S. Hydroboration with boron halides and trialkylsilanes. J. Org. Chem. 1990, 55, 2274-2275; (b) Soundararajan, R.; Matteson, D. S. Hydroboration with haloborane/trialkylsilane mixtures. Organometallics 1995, 14, 4157-4166; (c) Katz, B. A.; Finer-Moore, J.; Mortezaei, R.; Rich, D. H.; Stroud, R. M. Episelection: Novel Ki ~ nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. Biochemistry 1995, 34, 8264-8280; (d) Wityak, J.; Earl, R. A.; Abelman, M. M.; Bethel, Y. B.; Fisher, B. N.; Kauffman, G. S.; Kettner, C. A.; Ma, P.; McMillan, J. L. Synthesis of thrombin inhibitor DuP 714. J. Org. Chem. 1995, 60, 3717-3722; (e) Chen, X.; Bastow, K.; Goz, B.; Kucera, L.; Morris-Naatschke, S. L.; Ishaq, K. S. Boronic acid derivatives targeting HIV-1. Antiviral Chem. Chemother. 1996, 7, 108-114; (f) Chen, W.; Rockwell, J.; Knobler, C.; Hartwell, D.; Hawthorne, F. Synthesis and characterization of ortho-3-and meta-2-substituted carboranes through a boron-insertion reaction, including the structure of the product of a double-insertion reaction. Polyhedron 1999, 18, 1725-1734. ↩︎\nKanth, J. V. B.; Brown, H. C. Hydroboration. 97. Synthesis of new exceptional chloroborane-Lewis base adducts for hydroboration. Dioxane-monochloroborane as a superior reagent for the selective hydroboration of terminal alkenes. J. Org. Chem. 2001, 66, 5359-5365. ↩︎\nVedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. Conversion of arylboronic acids into potassium aryltrifluoroborates: Convenient precursors of arylboron difluoride Lewis acids. J. Org. Chem. 1995, 60, 3020-3027. ↩︎\nMolander, G. A.; Figureroa, R. Organotrifluoroborates: Expanding organoboron chemistry. Aldrichim. Acta. 2005, 38, 49-56. ↩︎\nBurke, S. J.; Gamrat, J. M.; Santhouse J. R.; Tomares, D. T.; Tomsho, J. W. Potassium haloalkyltrifluoroborate salts: Synthesis, application, and reversible ligand replacement with MIDA. Tetrahedron Lett. 2015, 56, 5500-5503. ↩︎\n","wordCount":"640","inLanguage":"en","image":"orgsyn-argon-gas.top/%3Clink%20or%20path%20of%20image%20for%20opengraph,%20twitter-cards%3E","datePublished":"2025-02-15T17:11:29+08:00","dateModified":"2025-02-15T17:11:29+08:00","author":{"@type":"Person","name":"Argon"},"mainEntityOfPage":{"@type":"WebPage","@id":"orgsyn-argon-gas.top/posts/orgsyn011/"},"publisher":{"@type":"Organization","name":"OrgSyn","logo":{"@type":"ImageObject","url":"orgsyn-argon-gas.top/%3Clink%20/%20abs%20url%3E"}}}</script></head><body id=top><script>localStorage.getItem("pref-theme")==="dark"?document.body.classList.add("dark"):localStorage.getItem("pref-theme")==="light"?document.body.classList.remove("dark"):window.matchMedia("(prefers-color-scheme: dark)").matches&&document.body.classList.add("dark")</script><header class=header><nav class=nav><div class=logo><a href=orgsyn-argon-gas.top/ accesskey=h title="OrgSyn (Alt + H)"><img src=/apple-touch-icon.png alt aria-label=logo height=35>OrgSyn</a><div class=logo-switches><button id=theme-toggle accesskey=t title="(Alt + T)"><svg id="moon" width="24" height="18" viewBox="0 0 24 24" fill="none" stroke="currentcolor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/></svg><svg id="sun" width="24" height="18" viewBox="0 0 24 24" fill="none" stroke="currentcolor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="5"/><line x1="12" y1="1" x2="12" y2="3"/><line x1="12" y1="21" x2="12" y2="23"/><line x1="4.22" y1="4.22" x2="5.64" y2="5.64"/><line x1="18.36" y1="18.36" x2="19.78" y2="19.78"/><line x1="1" y1="12" x2="3" y2="12"/><line x1="21" y1="12" x2="23" y2="12"/><line x1="4.22" y1="19.78" x2="5.64" y2="18.36"/><line x1="18.36" y1="5.64" x2="19.78" y2="4.22"/></svg></button></div></div><ul id=menu><li><a href=orgsyn-argon-gas.top/orgsyn-argon-gas.top/archives/ title=archive><span>archive</span></a></li><li><a href=orgsyn-argon-gas.top/orgsyn-argon-gas.top/about/ title=about><span>about</span></a></li><li><a href=orgsyn-argon-gas.top/orgsyn-argon-gas.top/search/ title="search (Alt + /)" accesskey=/><span>search</span></a></li></ul></nav></header><main class=main><article class=post-single><header class=post-header><div class=breadcrumbs><a href=orgsyn-argon-gas.top/>Home</a>&nbsp;»&nbsp;<a href=orgsyn-argon-gas.top/posts/>Posts</a></div><h1 class="post-title entry-hint-parent">OrgSyn011</h1><div class=post-meta><span title='2025-02-15 17:11:29 +0800 CST'>February 15, 2025</span>&nbsp;·&nbsp;4 min&nbsp;·&nbsp;640 words&nbsp;·&nbsp;Argon&nbsp;|&nbsp;<a href=https://github.com/%3cpath_to_repo%3e/content rel="noopener noreferrer" target=_blank>Suggest Changes</a></div></header><div class=toc><details><summary accesskey=c title="(Alt + C)"><span class=details>Table of Contents</span></summary><div class=inner><nav id=TableOfContents><ul><li><a href=#简述>简述</a></li><li><a href=#讨论>讨论</a></li><li><a href=#参考>参考</a></li></ul></nav></div></details></div><div class=post-content><p>本篇策略为卤代烯烃的硼氢化加成反应。原文：<em>Org. Synth.</em> <strong>2023</strong> , <em>100</em> , 218-233.</p><h2 id=简述>简述<a hidden class=anchor aria-hidden=true href=#简述>#</a></h2><p><img alt=011-1 loading=lazy src=https://img.z4a.net/images/2025/02/15/011-1.png></p><p>该反应表观上为烯烃的硼氢化过程。</p><p>反应首先在低温下加入 BCl3 和 Et3SiH 实现硼氢化加成，然后冰浴条件下加水将硼烷水解，最后再用 KHF2 作为氟代试剂生成氟硼酸钾盐产物<strong>3</strong>。</p><h2 id=讨论>讨论<a hidden class=anchor aria-hidden=true href=#讨论>#</a></h2><p>硼酸及衍生物在生物药物中常有出现，截至2023年底，美国食品药物管理局（FDA）已经批准了五个含硼的药物，分别是：Velcade®<sup id=fnref:1><a href=#fn:1 class=footnote-ref role=doc-noteref>1</a></sup>; Kerydin<sup id=fnref:2><a href=#fn:2 class=footnote-ref role=doc-noteref>2</a></sup>; Ninlaro®<sup id=fnref:3><a href=#fn:3 class=footnote-ref role=doc-noteref>3</a></sup>; Eucrisa<sup id=fnref:4><a href=#fn:4 class=footnote-ref role=doc-noteref>4</a></sup>; Vabomere<sup id=fnref:5><a href=#fn:5 class=footnote-ref role=doc-noteref>5</a></sup>。</p><p>硼在药物中应用的潜力来自于它的 Lewis 酸性，由于硼原子有一个空的 p 轨道，因此可以和 Lewis 碱相互作用，为其与酶的活性位点的氨基酸结合形成复合物提供了可能<sup id=fnref:6><a href=#fn:6 class=footnote-ref role=doc-noteref>6</a></sup>。</p><p>不过，硼的空轨道有时也会对合成造成影响，亲核试剂可能会被硼错误地捕获，无法起到原本的作用，因此人们逐渐探索出使用三氟硼酸盐来掩蔽硼的 Lewis 酸性的方法。</p><p>卤代烷烃的硼氢化反应已有大量报导，但是现有的反应仍然存在许多不足之处，如原子经济性低、产率低、试剂昂贵或所得产物不纯等等<sup id=fnref:7><a href=#fn:7 class=footnote-ref role=doc-noteref>7</a></sup>，因此仍需探索新的方案。</p><p>Brown 等人发现二氯硼烷+二氧六环，以及二溴硼烷+二甲硫醚的组合在反应成本上有很大优势，但是由于二卤代硼烷的歧化，反应副产物很多，产率较低<sup id=fnref:8><a href=#fn:8 class=footnote-ref role=doc-noteref>8</a></sup>。</p><p>作者团队基于此方案继续优化，为避免歧化反应，他们使用三氯化硼+三乙基硅烷原位制备二卤代硼烷。但是后处理，纯化后得到的产物产率仍然不理想，这一点与底物碳链长度和溶解度有关系，长链化合物（如下图化合物<strong>2</strong>）因为在水中溶解度低因此容易结晶析出，产率较好（79%）；短链化合物产率不佳（化合物<strong>2b</strong>， 27%；化合物<strong>2c</strong>，22% ）。</p><p><img alt=011-2 loading=lazy src=https://img.z4a.net/images/2025/02/15/011-2.png></p><p>产物<strong>2</strong>再用氟氢化钾处理得氟硼酸钾盐产物<strong>3</strong>，Vedejs<sup id=fnref:9><a href=#fn:9 class=footnote-ref role=doc-noteref>9</a></sup> 和 Molander<sup id=fnref:10><a href=#fn:10 class=footnote-ref role=doc-noteref>10</a></sup> 等人的研究表明这一反应易于得到较好的产率（62-90%）。</p><p>尽管得到了目标产物，但是两步反应的总产率并不高（14-71%），为提高反应的产率，作者团队再次进行了优化。最终，作者探索出了制备卤代烷烃氟硼酸钾盐的通用制备策略<sup id=fnref:11><a href=#fn:11 class=footnote-ref role=doc-noteref>11</a></sup>（上图中上侧的一步反应），将原本的两步反应简化为一锅法实现，并对各类底物都表现出良好的适用性，副产物少，原子经济性高，价格低廉，有很大的应用潜力。</p><p><img alt=011-3 loading=lazy src=https://img.z4a.net/images/2025/02/15/011-3.png></p><h2 id=参考>参考<a hidden class=anchor aria-hidden=true href=#参考>#</a></h2><div class=footnotes role=doc-endnotes><hr><ol><li id=fn:1><p>Baker, S. J.; Ding, C. Z.; Akama, T.; Zhang, Y. K.; Hernandez, V.; Xia, Y. Therapeutic potential of boron-containing compounds. Future Med. Chem. 2009, 1275-1288.&#160;<a href=#fnref:1 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:2><p>(a) Elewski, B. E.; Tosti, A. Tavaborole for the treatment of onychomycosis. Expert Opin. Pharmacother. 2014, 15, 1439-1448; (b) Hui, X.; Baker, S. J.; Wester, R. C.; Barbadillo, S.; Cashmore, A. K.; Sanders, V.; Hold, K. M.; Akama, T.; Zhang, Y. K.; Plattner, J. J.; Maibach, H. I. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J. Pharmaceut. Sci. 2007, 96, 2622-2631.&#160;<a href=#fnref:2 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:3><p>Hu, Q.; Liu, R.; Fang, Z.; Zhang, J.; Ding, Y.; Tan, M.; Wang, M.; Pan, W.; Zhou, H.; Wang, E. Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. Sci. Rep. 2013, 3, 2475.&#160;<a href=#fnref:3 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:4><p>Hernandez, V.; Crépin, T.; Palencia, A.; Cusack, S.; Akama, T.; Baker, S. J.; Bu, W.; Feng, L.; Freund, Y. R.; Liu, L.; Meewan, M.; Mohan, M.; Mao, W.; Rock, F. L.; Sexton, H.; Sheoran, A.; Zhang, Y.; Zhang, Y.-K.; Zhou, Y.; Nieman, J. A.; Anugula, M. R.; Keramane, E. M.; Savariraj, K.; Reddy, D. S.; Sharma, R.; Subedi, R.; Singh, R.; O&rsquo;Leary, A.; Simon, N. L.; De Marsh, P. L.; Mushtaq, S.; Warner, M.; Livermore, D. M.; Alley, M. R. K.; Plattner, J. J. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob. Agents Chemother. 2013, 57 (3), 1394-1403.&#160;<a href=#fnref:4 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:5><p>Messner, K.; Vuong, B.; Tranmer, G.K. The Boron Advantage: The Evolution and Diversification of Boron&rsquo;s Applications in Medicinal Chemistry. Pharmaceuticals 2022, 15, 264.&#160;<a href=#fnref:5 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:6><p>(a) Baker, S. J.; Tomsho, J. W.; Benkovic, S. J. Boron-containing inhibitors of synthetases. Chem. Soc. Rev. 2011, 40, 4279-4285; (b) Das, B. C.; Thapa, P.; Karki, R.; Schinke, C.; Das, S.; Kambhampati, S.; Banerjee, S. K.; Vam Veldhuizen, P.; Verma, A.; Weiss, L. M.; Evans, T. Boron chemicals in diagnosis and therapeutics. Future Med. Chem. 2013, 5, 653-676.&#160;<a href=#fnref:6 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:7><p>(a) Soundararajan, R.; Matteson, D. S. Hydroboration with boron halides and trialkylsilanes. J. Org. Chem. 1990, 55, 2274-2275; (b) Soundararajan, R.; Matteson, D. S. Hydroboration with haloborane/trialkylsilane mixtures. Organometallics 1995, 14, 4157-4166; (c) Katz, B. A.; Finer-Moore, J.; Mortezaei, R.; Rich, D. H.; Stroud, R. M. Episelection: Novel Ki ~ nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. Biochemistry 1995, 34, 8264-8280; (d) Wityak, J.; Earl, R. A.; Abelman, M. M.; Bethel, Y. B.; Fisher, B. N.; Kauffman, G. S.; Kettner, C. A.; Ma, P.; McMillan, J. L. Synthesis of thrombin inhibitor DuP 714. J. Org. Chem. 1995, 60, 3717-3722; (e) Chen, X.; Bastow, K.; Goz, B.; Kucera, L.; Morris-Naatschke, S. L.; Ishaq, K. S. Boronic acid derivatives targeting HIV-1. Antiviral Chem. Chemother. 1996, 7, 108-114; (f) Chen, W.; Rockwell, J.; Knobler, C.; Hartwell, D.; Hawthorne, F. Synthesis and characterization of ortho-3-and meta-2-substituted carboranes through a boron-insertion reaction, including the structure of the product of a double-insertion reaction. Polyhedron 1999, 18, 1725-1734.&#160;<a href=#fnref:7 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:8><p>Kanth, J. V. B.; Brown, H. C. Hydroboration. 97. Synthesis of new exceptional chloroborane-Lewis base adducts for hydroboration. Dioxane-monochloroborane as a superior reagent for the selective hydroboration of terminal alkenes. J. Org. Chem. 2001, 66, 5359-5365.&#160;<a href=#fnref:8 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:9><p>Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. Conversion of arylboronic acids into potassium aryltrifluoroborates: Convenient precursors of arylboron difluoride Lewis acids. J. Org. Chem. 1995, 60, 3020-3027.&#160;<a href=#fnref:9 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:10><p>Molander, G. A.; Figureroa, R. Organotrifluoroborates: Expanding organoboron chemistry. Aldrichim. Acta. 2005, 38, 49-56.&#160;<a href=#fnref:10 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li><li id=fn:11><p>Burke, S. J.; Gamrat, J. M.; Santhouse J. R.; Tomares, D. T.; Tomsho, J. W. Potassium haloalkyltrifluoroborate salts: Synthesis, application, and reversible ligand replacement with MIDA. Tetrahedron Lett. 2015, 56, 5500-5503.&#160;<a href=#fnref:11 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li></ol></div></div><footer class=post-footer><ul class=post-tags></ul><nav class=paginav><a class=prev href=orgsyn-argon-gas.top/posts/orgsyn012/><span class=title>« Prev</span><br><span>OrgSyn012</span>
</a><a class=next href=orgsyn-argon-gas.top/posts/orgsyn010/><span class=title>Next »</span><br><span>OrgSyn010</span></a></nav></footer></article></main><footer class=footer><span>&copy; 2025 <a href=orgsyn-argon-gas.top/>OrgSyn</a></span> ·
<span>Powered by
<a href=https://gohugo.io/ rel="noopener noreferrer" target=_blank>Hugo</a> &
        <a href=https://github.com/adityatelange/hugo-PaperMod/ rel=noopener target=_blank>PaperMod</a></span></footer><a href=#top aria-label="go to top" title="Go to Top (Alt + G)" class=top-link id=top-link accesskey=g><svg viewBox="0 0 12 6" fill="currentcolor"><path d="M12 6H0l6-6z"/></svg>
</a><script>let menu=document.getElementById("menu");menu&&(menu.scrollLeft=localStorage.getItem("menu-scroll-position"),menu.onscroll=function(){localStorage.setItem("menu-scroll-position",menu.scrollLeft)}),document.querySelectorAll('a[href^="#"]').forEach(e=>{e.addEventListener("click",function(e){e.preventDefault();var t=this.getAttribute("href").substr(1);window.matchMedia("(prefers-reduced-motion: reduce)").matches?document.querySelector(`[id='${decodeURIComponent(t)}']`).scrollIntoView():document.querySelector(`[id='${decodeURIComponent(t)}']`).scrollIntoView({behavior:"smooth"}),t==="top"?history.replaceState(null,null," "):history.pushState(null,null,`#${t}`)})})</script><script>var mybutton=document.getElementById("top-link");window.onscroll=function(){document.body.scrollTop>800||document.documentElement.scrollTop>800?(mybutton.style.visibility="visible",mybutton.style.opacity="1"):(mybutton.style.visibility="hidden",mybutton.style.opacity="0")}</script><script>document.getElementById("theme-toggle").addEventListener("click",()=>{document.body.className.includes("dark")?(document.body.classList.remove("dark"),localStorage.setItem("pref-theme","light")):(document.body.classList.add("dark"),localStorage.setItem("pref-theme","dark"))})</script></body></html>